Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G POTASSIUM IN PLASTIC CONTAINER versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G POTASSIUM IN PLASTIC CONTAINER versus PENICILLIN 2.
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER vs PENICILLIN-2
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Penicillin G is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Treatment of serious infections caused by susceptible gram-positive cocci (e.g., Streptococcus pneumoniae, group A streptococci), gram-negative cocci (e.g., Neisseria meningitidis), some gram-positive bacilli (e.g., Clostridium perfringens), and Treponema pallidum; also used for prophylaxis of bacterial endocarditis in patients with valvular heart disease undergoing dental or surgical procedures.
Streptococcal infectionsPneumococcal infectionsMeningococcal infectionsSyphilisLyme diseaseAnthraxActinomycosisProphylaxis for rheumatic fever
2-4 million units IV every 4 hours for moderate to severe infections; up to 24 million units/day for serious infections (meningitis, endocarditis).
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
0.5–1 hour (normal renal function). Prolonged in renal impairment (up to 7–10 hours in anuria).
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Penicillin G is primarily metabolized by hydrolysis to penicilloic acid, which is inactive. It is also metabolized via renal tubular secretion and glomerular filtration.
Primarily eliminated unchanged by renal tubular secretion; minor hepatic metabolism to penicilloic acid.
Renal: 60–90% unchanged via tubular secretion and glomerular filtration. Biliary/fecal: <10%.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Approximately 60% bound to serum albumin.
50-65% bound, primarily to albumin
0.3–0.5 L/kg; limited distribution, primarily extracellular fluid.
0.3-0.5 L/kg; low Vd indicates limited tissue penetration
IM: 60–80% due to partial degradation at injection site. Oral: Not applicable (acid-labile, not orally administered).
Oral: 60-70% (decreased with food); IM: 70-85%
CrCl >50 mL/min: no adjustment; CrCl 10-50 mL/min: administer every 6-8 hours; CrCl <10 mL/min: administer every 8-12 hours.
For CrCl 10-50 mL/min: administer every 8-12 hours; for CrCl <10 mL/min: administer every 12-18 hours; hemodialysis: give after dialysis.
No dose adjustment required for hepatic impairment.
No specific Child-Pugh based dose adjustment; use with caution in severe hepatic impairment.
Neonates: <7 days, 50,000 units/kg/dose IV every 12 hours; 7-28 days, 75,000 units/kg/dose IV every 8 hours. Infants and children: 100,000-250,000 units/kg/day IV divided every 4-6 hours; maximum 24 million units/day. For meningitis: 250,000-400,000 units/kg/day IV divided every 4-6 hours.
For children >1 month: 25-50 mg/kg/day orally divided every 6-8 hours; severe infections: 100-250 mg/kg/day IV divided every 4-6 hours; maximum 12 g/day.
Adjust dose based on renal function; consider lower initial doses due to age-related decline in GFR; monitor for electrolyte disturbances (hyperkalemia) and neurotoxicity.
No specific dose adjustment except for renal function; monitor renal function and adjust dose accordingly.
WARNING: SERIOUS HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS, HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. BEFORE INITIATING THERAPY, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, DISCONTINUE PENICILLIN G AND INSTITUTE APPROPRIATE THERAPY.
No FDA black box warning.
["Hypersensitivity reactions including anaphylaxis","Clostridium difficile-associated diarrhea","Electrolyte disturbances (hyperkalemia with potassium salt)","Neurologic adverse effects (seizures) with high doses or renal impairment","Thrombophlebitis at injection site","Use with caution in patients with renal impairment or history of allergies"]
["Hypersensitivity reactions including anaphylaxis","Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome)","Clostridioides difficile-associated diarrhea","Renal impairment requiring dose adjustment","Neurologic toxicity with high doses (seizures)"]
["History of hypersensitivity to any penicillin","Previous anaphylactic reaction to beta-lactam antibiotics"]
["Hypersensitivity to penicillins","History of severe immediate hypersensitivity reaction to beta-lactam antibiotics"]
Data Pending Review
Data Pending Review
No significant food-drug interactions. However, avoid alcohol consumption during treatment as it may exacerbate side effects or reduce efficacy. No dietary restrictions required.
No significant food interactions. Can be taken with or without food.
Penicillin G potassium is generally considered safe during pregnancy. No teratogenic effects have been reported in human studies across all trimesters. However, as with all medications, use only if clearly needed.
Penicillin is generally considered low risk; no significant teratogenic effects have been consistently reported in first trimester. Animal studies show no fetal harm. Use is considered safe across all trimesters when indicated.
Penicillin G is excreted into breast milk in low concentrations (M/P ratio approximately 0.1 to 0.2). Considered compatible with breastfeeding; risk to nursing infant is minimal.
Penicillin is excreted into breast milk in low concentrations (M/P ratio approximately 0.2). It is compatible with breastfeeding; no adverse effects on nursing infants reported. Caution in infants with history of penicillin allergy.
No dose adjustment is typically required during pregnancy, though increased plasma volume may slightly decrease serum concentrations. Standard dosing is generally effective.
Increased renal clearance in pregnancy may reduce serum concentrations; higher doses may be required for severe infections, but standard dosing is generally adequate. No specific dose adjustment is uniformly recommended; monitor clinical response.
Category A/B
Category C
Penicillin G potassium in plastic container is a first-line agent for syphilis, group A streptococcal infections, and prophylaxis for rheumatic fever. It is inactivated by gastric acid, so it must be administered parenterally (IV or IM). Monitor potassium levels in patients with renal impairment due to potassium content (~1.7 mEq per million units). Use caution in patients with history of severe allergy to penicillins; cross-reactivity with cephalosporins is low but possible. For neurosyphilis, high-dose IV therapy is required. Record via IV infusion over 1-2 hours to avoid vein irritation. In neonates, use only after cultures confirm need.
Penicillin-2 (benzathine penicillin G) is indicated for syphilis and group A streptococcal infections. Intramuscular injection only; avoid intravenous administration. Monitor for Jarisch-Herxheimer reaction. Dose adjustment in renal impairment is not typically required due to slow release.
This medication is given as an injection or infusion into a vein or muscle, not by mouth.Complete the entire course of therapy even if you feel better to prevent resistance.Notify your doctor immediately if you experience rash, hives, difficulty breathing, or swelling of the face or throat.This formulation contains potassium; if you have kidney problems, your doctor will monitor your potassium levels.Do not stop treatment early without consulting your healthcare provider.
Complete the full course as prescribed, even if symptoms improve.Report any rash, difficulty breathing, or swelling immediately.Avoid alcohol during treatment to minimize side effects.Do not stop or change the dose without consulting your doctor.Inform all healthcare providers about this therapy.